

DAFTAR PUSTAKA

1. WHO. Global Tuberculosis Report 2023. *World Health Organization*.2023.
2. WHO. Global Tuberculosis Report 2022. *World Health Organization*. 2022.
3. Kager LM, Blok DC, Lede IO, Rahman W, Afroz R, Bresser P, *et al*. Pulmonary tuberculosis induces a systemic hypercoagulable state. *J Infect*. 2015 Apr;70(4):324–34.
4. Ha H, Kim KH, Park JH, Lee JK, Heo EY, Kim JS, *et al*. Thromboembolism in Mycobacterium tuberculosis Infection: Analysis and Literature Review. *Infect Chemother*. 2019;51(2):142–9.
5. Suryakusumah L, Tabri NA, Saleh S, Bakri S, Kasim H, Benyamin AF, *et al*. Hemostatic parameters in pulmonary tuberculosis patients after intensive phase treatment. *Casp J Intern Med*. 2021;12(3):294–8.
6. Isbaniah F, Burhan E, Sinaga BY, Behtri D, Handayani D, Agustin H, *et al* Tuberkulosis: Pedoman Diagnosis dan Penatalaksanaan di Indonesia. *PDPI*. 2021.
7. Aynalem M, *et al*. Coagulopathy and its associated factors among patients with a bleeding diathesis at the University of Gondar Specialized Referral Hospital, Northwest Ethiopia. *Thrombosis journal*, 2021, 19: 1-12.
8. Kutiya AS, Gupta N, Garg S, Hira HS. A Study of Haematological and Haemostasis Parameters and Hypercoagulable State in Tuberculosis Patients in Northern India and the Outcome with Anti-Tubercular Therapy. *J Clin Diagn Res*. 2017;11(2):OC09-OC13.
9. Raychaudhuri S, Menia R, Yadav P. Assessment of Hematological and Coagulation profile of patients diagnosed as Tuberculous lymphadenopathy on cytology: A cross sectional study in Industrial belt in Northern India. *IP J Diagn Pathol Oncol*. 2022;7(1):30–5.
10. Hanson, Stephen R., Tucker, Erik I., Latour, Robert A., Blood coagulation and blood–material interactions. *In: Biomaterials science*. Academic Press, 2020; 801-812
11. Sasindran SJ, Torrelles JB. Mycobacterium Tuberculosis Infection and Inflammation: what is Beneficial for the Host and for the Bacterium?. *Front Microbiol*. 2011;2:2.

12. Maison DP. Tuberculosis pathophysiology and anti-VEGF intervention. *J Clin Tuberc Mycobact Dis.* 2022;27:100300.
13. Balepur SS, Schlossberg D. Hematologic Complications of Tuberculosis. Schlossberg D, editor. *Microbiol Spectr.* 2016;4(6):4.6.46.
14. Caccamo N, Dieli F. Inflammation and the coagulation system in tuberculosis: Tissue Factor leads the dance. *Eur J Immunol.* 2016;46(2):303–6.
15. Okoroiwu IL, Obeagu EI, Anaebio QBN, Walter O. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *J Pharm Res Int.* 2022;29–34.
16. Akpan PA, Akpotuzor JO, Osim EE. Haemostatic Indices as Markers for Monitoring Pulmonary Tuberculosis Treatment. *Niger J Physiol Sci.* 2018;33(1):31–5.
17. Sillen M, Declerck PJ. A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target? *Int J Mol Sci.* 2021;22(5):2721.
18. Kumaravel, Ashwinamurthy, et al. A Study on Haematological and Coagulation Parameters in Newly Diagnosed Tuberculosis Patients. *European Journal of Cardiovascular Medicine*, 2024, 14.2.
19. Muzaffar TM, Shaifuzain AR, Imran Y, Haslina MN. 2008. Hematological changes in tuberculous spondylitis patients at the Hospital Universiti Sains Malaysia. *Southeast Asian J Trop Med Public Health.* 39:686–689.
20. Mitroi, D.M.; Balteanu, M.A.; Cioboata, R.; Vlasceanu, S.G.; Zlatian, O.M.; Catana, O.M.; Mirea, A.A.; Mogos, G.F.R.; Rotaru, I.; Biciusca, V. Hypercoagulability in Tuberculosis: Pathophysiological Mechanisms, Associated Risks, and Advances in Management—A Narrative Review. *J. Clin. Med.* 2025, 14, 762. <https://doi.org/10.3390/jcm14030762>
21. Shaikh SM, Toshniwal S, Wanjari A, Acharya S, Kumar S. Anti-Tubercular-Therapy-Induced Severe Thrombocytopenia Presenting as a Vocal Cord Bleed With Massive Hemoptysis Causing Mortality: A Catastrophic Combination. *Cureus.* 2024 Feb 7;16(2):e53752. doi: 10.7759/cureus.53752. PMID: 38468983; PMCID: PMC10927158.
22. WHO. Global Tuberculosis Report 2023. *World Health Organization.* 2024.

23. Ionut-Valentin Stanciu, Ariadna-Petronela Fildan, Barkha Rani Thakur, Adrian Cosmin Ilie, Livia Stanga, Cristian Oancea, Emanuela Tudorache, Felix Bratosin, Ovidiu Rosca, Iulia Bogdan, Anca Chisoi, Ionela Preotesoiu, Viorica Zamfir, Elena Dantes, Full-Blood Inflammatory Ratios Predict Length of Stay but Not Early Death in Romanian Pulmonary Tuberculosis, *Medicina*, 10.3390/medicina61071238, **61**, 7, (1238), (2025).
24. Lubis, M. E., Lukito, A., Dianitha, E., Yuridzaky, A., & Kiram, G. Y. (2025). *Hubungan perilaku merokok dengan kejadian penyakit tuberkulosis paru di wilayah kerja UPT Puskesmas Medan Teladan periode Desember 2024 – Januari 2025*. Stikes Mitra Sejati & Universitas Islam Sumatera Utara.
25. Eyob L, Ali H, Adisu Y, Tesfaye A. Determinants of weight gain among adult tuberculosis patients on dots during intensive phase in Wonago Ethiopia, unmatched case control study. *Sci Rep*. 2025 Apr 12;15(1):12556. doi: 10.1038/s41598-025-97265-z. PMID: 40221519; PMCID: PMC11993581.
26. Amaltullah, D. S., Oktayana, I. P., Sahadewa, S., & Putri, D. D. (2024). Hubungan indeks massa tubuh (IMT) sebagai faktor risiko kejadian tuberkulosis (TB) paru di Puskesmas Modopuro. *Prosiding Seminar Nasional Kusuma III*, 2, eISSN: 3062-9365.
27. Ampow, A. T., Timban, J. F. J., & Rondo, A. G. E. Y. (2023). Gambaran foto toraks pasien tuberkulosis paru dengan efusi pleura di RSUP Prof. Dr. R. D. Kandou periode Januari–Juni 2022 [Chest X-ray of tuberculosis patients with pleural effusion at Prof. Dr. R. D. Kandou Hospital from January to June 2022]. *Jurnal Biomedik (JBM)*, 15(2), 161–169. <https://doi.org/10.35790/jbm.15.2.2023.42015>
28. Taqarrasya, A., Wikandari, R. J., & Rosidah, U. (2023). Perbedaan jumlah trombosit pada pasien TB sebelum dan setelah 1 bulan mengonsumsi obat anti TB [Difference of platelet count in patients with tuberculosis before and after 1 month of treatment with anti tuberculosis drug]. *Jurnal Analis Kesehatan Indonesia*, 12(2), 101–108. <https://doi.org/10.xxxx/jaki.v12i2.xxxx>
29. 'Izzuddin, M. A., Putri, N. A., & Sugihantono, A. (2024). Jumlah trombosit metode otomatis pada pengguna obat anti tuberkulosis di Puskesmas Kedungmundu. *Jurnal Medika*, 9(2), [halaman tidak tersedia]. <https://doi.org/10.53861/jmed.v9i2.476>
30. Kumaravel, A., Jadhav, P. N., Sahu, S., Athavale, A., Joshi, R. V., Singh, A., & Samuel, S. J. (2024). A study on haematological and coagulation parameters in newly diagnosed tuberculosis patients.

European Journal of Cardiovascular Medicine, 14(2), 234–240.
<https://www.healthcare-bulletin.co.uk/article/A-study-on-haematological-and-coagulation-parameters-in-newly-diagnosed-tuberculosis-patients>

31. Ittermann T, Feig MA, Petersmann A, Radke D, Greinacher A, Voßzke H, et al. (2019) Mean platelet volume is more important than age for defining reference intervals of platelet counts. *PLoS ONE* 14(3): e0213658. [https://doi.org/ 10.1371/journal.pone.0213658](https://doi.org/10.1371/journal.pone.0213658).
32. Donkin, R., Fung, Y. L., & Singh, I. (2023). Fibrinogen, coagulation, and ageing. In J. R. Harris & V. I. Korolchuk (Eds.), *Biochemistry and cell biology of ageing: Part III biomedical science* (pp. 313–342). Springer International Publishing. https://doi.org/10.1007/978-3-031-21410-3_12
33. Toppo, A., Varma, S., Khare, R. L., & Malhotra, Y. (2015). Study of bleeding and coagulation profile in patients of pulmonary tuberculosis in a tertiary care hospital in Chhattisgarh. *International Journal of Contemporary Medical Research*, 2(4), 932–937.
34. Wang, E. Y., Arrazola, R. A., Mathema, B., Ahluwalia, I. B., & Mase, S. R. (2020). The impact of smoking on tuberculosis treatment outcomes: A meta-analysis. *International Journal of Tuberculosis and Lung Disease*, 24(2), 170–175. <https://doi.org/10.5588/ijtld.19.0002>.
35. Iglesias Morcillo, M.; Freuer, D.; Peters, A.; Heier, M.; Meisinger, C.; Linseisen, J. Body Mass Index and Waist Circumference as Determinants of Hemostatic Factors in Participants of a Population-Based Study. *Medicina* 2023, 59, 228. <https://doi.org/10.3390/medicina59020228>
36. Urbanowski, M. E., Ordonez, A. A., Ruiz-Bedoya, C. A., Jain, S. K., & Bishai, W. R. (2020). Cavitory tuberculosis: The gateway of disease transmission. *The Lancet Infectious Diseases*, 20(6), e117–e128. [https://doi.org/10.1016/S1473-3099\(20\)30148-1](https://doi.org/10.1016/S1473-3099(20)30148-1)
37. Nurannisya, R., Najmah, N., Apritama, F., Dianita, N. R., Waruwu, P. D. K., Khoirunnisa, K., Pridamayanti, A., Harmadi, H., Putri, R. S., & Ruliansyah, D. (2025). *Distribusi kasus tuberculosis paru menurut usia, jenis kelamin, dan capaian program di Puskesmas Bukit Sangkal, Palembang tahun 2024*. *Jurnal Kesehatan Jompa (JUKEJ)*, 4(1), 1–10. <https://jurnal.jomparnd.com/index.php/jkj>
38. Ambrose, J. A., & Barua, R. S. (2004). The pathophysiology of cigarette smoking and cardiovascular disease: An update. *Journal of the*

American College of Cardiology, 43(10), 1731–1737.
<https://doi.org/10.1016/j.jacc.2003.12.047>

39. Ackermann, DA, Linneberg, A., Rastoder, E., Vognsen, AK, Bjerregaard, AA, Friis-Hansen, L., Jørgensen, NR, Hedsund, CE, Johansen, ND, Modin, D., Dons, M., Højbjerg Lassen, MC, Grundtvig Skaarup, K., Vesterlev, D., Moberg, M., Janner, J., Eklöf, J., Pedersen, L., Bendstrup, E., ... Sivapalan, P. (2025). Status Vitamin K Rendah dan Risiko Penyakit Paru Obstruktif Kronik. *Biomedis*, 13 (4), 807. <https://doi.org/10.3390/biomedicines13040807>
40. Elkhailifa AM. Effects of cigarette smoking on coagulation screening tests and platelet counts in a Sudanese male adults population. *Saudi Med J*. 2018 Sep;39(9):897-901. doi: 10.15537/smj.2018.9.22630. PMID: 30251733; PMCID: PMC6201005.
41. Făcă, A. I., Udeanu, D. I., Arsene, A. L., Mahler, B., Drăgănescu, D., & Apetroaei, M.-M. (2025). Nutritional Deficiencies and Management in Tuberculosis: Pharmacotherapeutic and Clinical Implications. *Nutrients*, 17(11), 1878. <https://doi.org/10.3390/nu17111878>
42. Praveček M, Miškić B. Diagnostic complexity of rifampicin-induced coagulopathy in a patient with spontaneous muscle bleeding: a case report. *Medicine*. 2021;100:26(e26234)
43. Nakane, C., Nishimoto, K., Kishimoto, E., Suzuki, K., Nakagawa, E., Morikawa, M., Murakami, Y., Aoshima, Y., Matsushima, S., Harada, M., Uto, T., & Imokawa, S. (2023). A case of severe thrombocytopenia after the first exposure to rifampicin. *Respiratory Medicine Case Reports*, 42, 101823. <https://doi.org/10.1016/j.rmcr.2023.101823>
44. Stevens, R. W., Rivera, C. G., Suh, G. A., Castillo Almeida, N. E., & Gurram, P. (2021). Cefazolin and rifampin: A coagulopathy-inducing combination. *American Journal of Health-System Pharmacy*, 78(24), 2204–2208. <https://doi.org/10.1093/ajhp/zxab210>
45. Awang, H., NR, N. H., & Abdullah, H. (2019). Chest radiographic findings and clinical determinants for severe pulmonary tuberculosis among children and adolescents in Malaysia. *Russian Open Medical Journal*, 8(2), 210.
46. Wallis RS, Peppard T, Hermann D. Clinical symptoms and microbiological outcomes in tuberculosis treatment trials. *Tuberculosis (Edinb)*. 2011;91 Suppl 1:S6–S9Lee

47. Allwood BW, van der Zalm MM, Amaral AFS, et al. Post-tuberculosis lung health: perspectives from the First International Symposium. *Int J Tuberc Lung Dis*. 2020;24(8):820–828.
48. Meghji J, Simpson H, Squire SB, Mortimer K. A systematic review of the prevalence and pattern of imaging-defined post-TB lung disease. *PLoS One*. 2016;11(8):e0161176.
49. Byrne AL, Marais BJ, Mitnick CD, et al. Chronic airflow obstruction after successful treatment of tuberculosis. *Lancet Infect Dis*. 2015;15(9):1039–1046.
50. Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: from epidemiology to pathophysiology. *Eur Respir Rev*. 2018;27:170077.